Effects of alkylated-chitosan-DNA nanoparticles on the function of macrophages

Journal of Materials Science: Materials in Medicine

Volumn 20, Issue 4, 2009, Pages 943-948

  Liu, L X ^a   Song, C N ^a   Song, L P ^a   Zhang, H L ^a   Dong, X ^a   Leng, X G ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYL GROUPS; CELL TRANSFECTIONS; CONCENTRATION OF; CYTOKINES; DNA CONTENTS; ELECTROSTATIC INTERACTIONS; ENZYMATIC DEGRADATIONS; INFLAMMATORY CYTOKINES; MURINE MACROPHAGES; NEGATIVE CONTROLS; NEGATIVE IMPACTS; PHAGOCYTIC ACTIVITIES; SIGNIFICANT IMPACTS; TRANSGENIC;

ALKYLATION; BIOCOMPATIBILITY; CHITOSAN; DNA; GENES; MACROPHAGES; NANOPARTICLES; NUCLEIC ACIDS;

CHITIN;

CHITOSAN; DNA; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CYTOKINE PRODUCTION; DNA CONTENT; INCUBATION TIME; MACROPHAGE FUNCTION; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL;

ALKYLATION; ANIMALS; BIOCOMPATIBLE MATERIALS; CELL LINE; CHITOSAN; CYTOKINES; DNA; ENZYME-LINKED IMMUNOSORBENT ASSAY; INFLAMMATION MEDIATORS; MACROPHAGES; MICE; NANOPARTICLES; PHAGOCYTOSIS;

MURINAE;

EID: 61349126486     PISSN: 09574530     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10856-008-3621-0     Document Type: Article

References (23)

1. SC Richardson HV Koibe R Duncan 1999 Int. J. Pharm. 178 231 10.1016/S0378-5173(98)00378-0
2. HQ Mao K Roy VL Troung-Le KA Janes KY Lin Y Wang JT August KW Leong 2001 J. Control Release 70 399 10.1016/S0168-3659(00)00361-8
3. VA Bloomfield 1996 Curr. Opin. Struct. Biol. 6 334 10.1016/S0959-440X(96) 80052-2
4. FC Maclaughlin RJ Mumper J Wang JM Tagliaferri I Gill M Hinchcliffe 1998 J. Control Release 56 259 10.1016/S0168-3659(98)00097-2
5. K Corsi F Chellat L Yahia JC Femandes 2003 Biomaterials 24 1255 10.1016/S0142-9612(02)00507-0
6. P Erbacher S Zou T Bettinger AM Steffan JS Remy 1998 Pharm. Res. 15 1332 10.1023/A:1011981000671
7. S Mansouri P Lavigne K Corsi M Benderdour E Beaumont JC Fernandes 2004 Eur. J. Pharm. Biopharm. 57 1 10.1016/S0939-6411(03)00155-3
8. WG Liu KD Yao 2002 J. Control Release 83 1 10.1016/S0168-3659(02)00007-X
9. SA Agnihotri NN Mallikarjuna TM Aminabhavi 2004 J. Control Release 100 5 10.1016/j.jconrel.2004.08.010
10. WG Liu X Zhang SJ Sun GJ Sun KD Yao 2003 J. Bioconjug. Chem. 14 782 10.1021/bc020051g
11. S Ercelen X Zhang G Duportail C Grandfils J Desbrieres S Karaeva V Tikhonov Y Mely V Babak 2006 Colloids Surf. B Biointerfaces 51 140 10.1016/j.colsurfb.2006.06.008
12. V Kanchan AK Panda 2007 Biomaterials 28 5344 10.1016/j.biomaterials.2007. 08.015
13. B Rothen-Rutishauser C Mühlfeld F Blank C Musso P Gehr 2007 Part. Fibre Toxicol. 4 9
14. AS Zahr MV Davis CA Pishko 2006 Langmuir 22 8178 10.1021/la060951b
15. F Chellat A Grandjean-Laquerriere R Le Naour J Femandes L Yahia M Guenounou 2005 Biomaterials 26 961 10.1016/j.biomaterials.2004.04.006
16. KG Ong JM Leland K Zeng G Barrett M Zourob CA Grimes 2006 Biosens. Bioelectron. 21 2270 10.1016/j.bios.2005.11.007
17. CM Sayes KL Reed DB Warheit 2007 Toxicol. Sci. 97 163 10.1093/toxsci/kfm018
18. EJ Anderson MA Mcgrath TT Halhamer IB Mcinnes 2006 Springer Semin. Immunopathol. 27 425 10.1007/s00281-006-0011-x
19. JL Mege S Meghari A Honstettre C Capo D Raoult 2006 Lancet Infect. Dis. 6 557 10.1016/S1473-3099(06)70577-1
20. A Taylor J Verhagen K Blaser M Akdis C Akdis 2006 Immunology 117 433 10.1111/j.1365-2567.2006.02321.x
21. VE Kagan H Bayir AA Shvedova 2005 Nanomedicine 1 313
22. Z Cui J Patel M Tuzova P Ray R Phillips JG Woodward 2004 Vaccine 22 2631 10.1016/j.vaccine.2003.12.013
23. CJ Johnston JN Finkelstein P Mercer N Corsor R Gelein G Oberdorster 2000 Toxicol. Appl. Pharmacol. 168 208 10.1006/taap.2000.9037